Blue Edge Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$687K Hold
5,377
0.09% 90
2025
Q4
$656K Hold
5,377
0.09% 90
2025
Q3
$539K Hold
5,377
0.08% 90
2025
Q2
$446K Hold
5,377
0.07% 96
2025
Q1
$436K Hold
5,377
0.07% 92
2024
Q4
$484K Hold
5,377
0.08% 88
2024
Q3
$531K Hold
5,377
0.08% 86
2024
Q2
$499K Hold
5,377
0.08% 88
2024
Q1
$510K Buy
+5,377
New +$499K 0.09% 88

Other funds holding XBI

Blue Edge Capital's XBI Position: Q1 2026 in Review

Blue Edge Capital held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q1 2026 at 5,377 shares worth $687K. The position accounts for 0.09% of the portfolio, ranked #90.

Blue Edge Capital first reported a position in XBI in Q1 2024 and has held it in 9 quarters since. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Blue Edge Capital held 5,377 shares of State Street SPDR S&P Biotech ETF worth $687K as of Q1 2026.
  • Blue Edge Capital left its State Street SPDR S&P Biotech ETF share count unchanged in Q1 2026.
  • State Street SPDR S&P Biotech ETF made up 0.09% of Blue Edge Capital's portfolio in Q1 2026, its #90 holding.
  • Blue Edge Capital first reported a position in State Street SPDR S&P Biotech ETF in Q1 2024 and has held it in 9 quarters since.
  • 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Blue Edge Capital's 13F filing for Q1 2026, filed 2 Jun 2026.